We still have 2 places left in our “SMART” study if you have type 1 diabetes and are aged 18-50! See below for a full list of research opportunities…

Learn all about how we developed an interactive research activity and in person research event with young people living with T1D with the help of @britsocimm, @BT1DUK, @BioRadEducation kits, the Steve Morgan Foundation, and a team of fantastic people! immunology.org/news/cardiff-…

Could the next generation of type 1 diabetes treatments come from better timing, better combinations, or better cells? Across the UK, researchers are working together in the #Type1DiabetesGrandChallenge to find answers. They're asking: - Could the time of day an immunotherapy is given make it more effective at slowing the immune attack? - Could combining immunotherapies, to target different parts of the immune system, provide better protection for insulin-producing cells? - How can we strengthen insulin-producing cells before transplantation so they're more likely to survive in the body? Mollie Hillis travelled from Birmingham to Edinburgh to meet the teams behind this research and discover how collaboration is accelerating progress towards new treatments. Because answering big questions takes big ideas - and, importantly, people working together. Read more: bit.ly/4yeq7qN #T1D #GBDoc #Research @DiabetesUK

Does your family plan on joining us at our Discovery Day in London next Saturday? We'd love to hear from you! 👂 We're looking for families to join us for a quick and informal session, to help us understand the information and support that were most useful to you since diagnosis. Your opinion will help us shape and improve the support we give to newly diagnosed families. 💙 We're incredibly thankful to The Bukhman Foundation for supporting our Community Engagement work! Tap the link and sign up today: bit.ly/3UUYNiB 🔗 #DiscoveryDay #GBDoc #BreakthroughT1D

We are recruiting three volunteers for the Scientific Advisory Council (SAC)🚨 The purpose of the SAC is to provide insightful, independent advice and critical opinions to Breakthrough T1D by guiding our research decisions, policies and position statements.   We are looking for: - One expert by experience (18-22 y/o) - One healthcare professional (dietitian)  - One clinical researcher Find out more about these roles: bit.ly/4cB3xQk 🔗

Could the time an immunotherapy treatment is given make it more effective for people with type 1 diabetes? That's the question Dr James Pearson and his team are exploring. Their research is investigating whether delivering treatment when protective immune cells (Tregs) are most 'awake' could improve its ability to slow or prevent the immune system from attacking insulin-producing cells. It's an innovative approach that could help unlock more effective immunotherapies for type 1 diabetes. Read more about the project here: bit.ly/49w2flG @DiabetesUK #Type1Diabetes #GBDoc #Type1DiabetesGrandChallenge

BCHC Community Connexions. We remain deeply appreciative of the £2,000 contribution received, from The ELSA study @elsadiabetes who had taken on fundraising challenges, which will support @BCHC_CommCX in organising approximately 2–3 further Community Clinics.

Meet the team behind the ELSA study: Consultant receives national recognition for leading pioneering T1D research @uhbtrust @unibirmingham @parthnarendran @RenukaDias @JAPearsonLab uhb.nhs.uk/news-and-events/n…

the ELSA study team Celebrated RCP Excellence in Patient Care Awards, these awards celebrate the outstanding contributions of RCP members and fellows worldwide, who are driving improvements in patient care through education, clinical practice, research and policy. @unibirmingham

Still 6 weeks left to join our “SMART” study if you have type 1 diabetes and are aged 18-50! See below for a full list of research opportunities…

Last month the NHS announced the approval of Teplizumab which is the first immunotherapy for #T1D & has been shown to delay onset. Part of this is finding people at risk. That’s where @T1DRA comes in – Sign up today to find out your risk of developing type 1 diabetes

Understanding T1D Burnout: National Survey: Before you decide whether or not to take part, it is important for you to understand why the research is being done and what it will involve 👇 click on link app.onlinesurveys.jisc.ac.uk… @JAPearsonLab @T1DRAdiabetes @parthnarendran

Thank you to all the researchers improving the lives of people living with, or at risk of, Type 1 diabetes

A day where we celebrate the work of the ELSA study researchers making a difference to people's lives, not just in Birmingham but the UK. @unibirmingham @parthnarendran @RenukaDias @T1DRAdiabetes @BristolUni @BT1DUK @DiabetesUK @JAPearsonLab @AlexRichter3

Research Appreciation Day: Medical science has proven time and again that when the resources are provided, great progress in the treatment, cure, and prevention of disease can occur. @BirminghamBRC @unibirmingham @parthnarendran @BT1DUK @DiabetesUK @RenukaDias @JAPearsonLab 👩‍🔬🔬

Research Appreciation Day 5th July: Behind every medical breakthrough is a team of dedicated health researchers. Thank you for your tireless fight to improve lives and bring hope to patients worldwide. @T1DRAdiabetes @parthnarendran @unibirmingham @NIHRresearch 👩‍🔬🩸🔬💊

@T1DRAdiabetes (ages 8-70) & @elsadiabetes (ages 2-17) are the only studies screening for #T1D risk autoantibodies in the UK. With the recent approval of Teplizumab, this is more important than ever. Sign up today to find out your eligibility for clinical trials/Tzield treatment

“Yesterday's landmark approval of teplizumab marks the start of a new age of type 1 diabetes treatment. “For the first time in 100 years, we are moving beyond insulin, with a medicine that targets the root cause of the condition.” Do you have any questions for the team

Today, history has been made: NICE has approved teplizumab for use on the NHS in England and Wales. Teplizumab is the first ever immunotherapy that can delay the onset of type 1 diabetes symptoms for people in the early stages of the condition. For the first time, we’re not just managing type 1 - we’re changing its course. This milestone means many things. But above all, it means time. More time to simply be a child. A reduction in emergency diagnoses and serious complications like diabetic ketoacidosis. A softer landing for individuals and families suddenly facing management of a life-long condition, and with it, renewed hope for the future. And this achievement belongs to you, our community. Breakthrough T1D funded early-stage research and the clinical trials that made teplizumab a reality. This breakthrough was made possible by your belief and support. Together, we are changing what’s possible. 💙 Read the full story here: bit.ly/4oJQzoo #GBDoc #Type1Diabetes #Teplizumab

A hugely exciting day - Teplizumab has been approved for use in early stage Type 1 diabetes aimed at delaying progression to insulin start. A step change in how we manage Type 1 diabetes and first new drug in over 100 years. Moving us towards insulin free Type 1 Diabetes 1/2